Arch Therapeutics, Inc.
Arch Therapeutics, Inc. (ARTH) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
arth · pe ratio · data through Sep 30, 2023
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Arch Therapeutics, Inc. (ARTH) measures how much investors pay for each dollar of the company's trailing earnings. ARTH's current PE ratio of N/A is calculated by dividing its stock price of $0.00 by its TTM earnings per share of -$2.27.
Source: FMP · /ratios-ttm · /analyst-estimates · 2023-09-30
PE Ratio History
2011 – 2023 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Arch Therapeutics, Inc.You ARTH | $0M | N/A | — | -$2.27 |
 ACI Global Corporation ACGJ | $0M | N/A | — | — |
 Allena Pharmaceuticals, Inc. ALNAQ | $0M | N/A | — | -$0.73 |
 Beleave Inc. BLEVF | $0M | N/A | — | -$0.08 |
 IMV Inc. IMVIQ | $0M | N/A | — | -$4.55 |
 MDEChem, Inc. MDKM | $0M | N/A | — | — |
 Micron Solutions, Inc. MICRD | $0M | N/A | — | -$0.41 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2023-09-30Latest FY2023 | — | $-2.27 | — | |
2022-09-30 FY2022 | — | $-3.56 | — | |
2021-09-30 FY2021 | — | $-5.97 | — | |
2020-09-30 FY2020 | — | $-4.27 | — | |
2019-09-30 FY2019 | — | $-3.27 | — | |
2018-09-30 FY2018 | — | $-6.30 | — | |
2017-09-30 FY2017 | — | $-10.91 | — | |
2016-09-30 FY2016 | — | $-9.87 | — | |
2015-09-30 FY2015 | — | $-7.24 | — | |
2014-09-30 FY2014 | — | $-24.13 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Arch Therapeutics, Inc. (ARTH) measures how much investors pay for each dollar of the company's trailing earnings. ARTH's current PE ratio of N/A is calculated by dividing its stock price of $0.00 by its TTM earnings per share of -$2.27.
Frequently asked questions
ARTH pe ratio · 6 questionsARTH's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.00 and TTM EPS of -$2.27. Data sourced from Financial Modeling Prep via ARTH's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Arch Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09